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Bone metastases represent a serious complication to several
cancers, in particular breast, lung, and prostate cancer. Since
their presence influences prognosis and management, they
must be searched for. Thus, the introduction of skeletal radio-
nuclide imaging with 18F-NaF (NaF) 55 years ago was a major
achievement [1], as was its replacement, scintigraphy with
bone-seeking phosphates [2], until computed tomography
(CT), magnetic resonance imaging (MRI), and once again
NaF in the shape of NaF-positron emission tomography/CT
(NaF-PET/CT) began contending for precedence. However,
this development took place gradually, without anybody ask-
ing the central questions: What are skeletal metastases, how
do they arise, and how do we best discover them?
A search of the Internet does not yield proper answers.
From Wikipedia [3], it appears that:
– BBone metastases generally arise from epithelial tumors
and form a solid mass inside the bone.^ BBone is the third
most common location for metastasis, after the lung and
liver. While any type of cancer is capable of forming
metastatic tumors within bone, the microenvironment of
the marrow tends to favor particular types of cancer, in-
cluding prostate, breast, and lung cancers. Particularly in
prostate cancer, bonemetastases tend to be the only site of
metastasis. The most common sites of bone metastases
are the spine, pelvis, ribs, skull, and proximal femur^
(Fig. 1) [3].
Wikipedia articles may be changed or edited frequently and
thus cannot be taken as peer-reviewed scientific material. If
instead one turns to professional websites like those of the
Mayo Clinic or the American Cancer Society [4, 5], one can
read:
– BUnder normal conditions, bone undergoes a continuous
remodeling through osteoclast-mediated bone resorption
and osteoblast-mediated bone deposition. These process-
es are normally tightly regulated within bone to maintain
bone structure and calcium homeostasis in the body.
Dysregulation of these processes by tumor cells leads to
either osteoblastic or osteolytic phenotypes, reflective of
the underlying mechanism of development. Typically,
osteolytic metastases are more aggressive than osteoblas-
tic metastases, which have a slower course. Regardless of
the phenotype, though, bone metastases show osteoclast
proliferation and hypertrophy^ [4].
– BBone metastasis can occur in any bone but more com-
monly occurs in the spine, pelvis and thigh. Bone metas-
tasis may be the first sign that you have cancer, or bone
metastasis may occur years after cancer treatment^ [5].
None of these sites clearly specify what bone metastases
are, how they occur, or how best to detect them, even though
they mention Bmedical imaging^ and biopsy. The Wikipedia
webpage on bonemarrow does not once mention bonemarrow
metastases or bone metastases, and its section on BImaging^
deals exclusively with CT, conventional x-ray, and MRI—not
PET [6]. The American Cancer Society Guidelines for the
Early Detection of Cancer [7] and its guidelines for the early
detection of breast, lung, and prostate cancer specifymammog-
raphy, CT, and MRI, without mentioning bone metastases or
PET. The same goes for the 2007 World Health Organization
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(WHO) guideline for early cancer control [8] and the recent EU
publication Cancer Screening in the European Union [9].
Oncologists and radiologists often refer to the Response
Evaluation Criteria in Solid Tumors (RECIST) guideline,
which designates lesion size of at least 10 mm as a criterion
formalignancy, which of course does notmake sense, and does
so without mentioning bone or bone marrow metastases [10].
Hoping to finally learn about how to examine for skeletal me-
tastasis, we took a look at the elaborate Danish National inte-
grated cancer pathways, supported by the Danish government
and the five Danish regions [11]. They have since 2009 guided
management of all cancer patients in the country, where 95%
of healthcare is free and public. However, not one of 29 path-
ways mention PET as a potential first-line examination in any
cancer, not even lung, and we could not find a single one
telling how to diagnose skeletal metastases [12].
Amazing to say: none of these official expert consensus
documents distinguish between what happens in the bone
marrow and bone matrix or describe when and how osseous
bone is affected. They list conventional x-ray, CT, and MRI
for screening or as first-line diagnostic imaging modalities,
saying almost nothing about detection of skeletal metastases.
This lack is in stark contrast to the fact that the presence or
absence of metastases, including skeletal metastases, is crucial
for the choice of treatment, as illustrated by the recent heated
debate regarding whether aggressive and more targeted ther-
apy in patients with so-called oligometastatic disease is justi-
fied, the rationale being that this may increase life expectancy
of selected cancer patients [13–16].
In short, guidelines and recommendations neglect, disre-
gard, or minimize the importance of bone marrow metastases,
their pathobiology, and how to best diagnose them at an early
time point, when they are supposedly more easily treatable.
This is an unfortunate trend in the twenty-first century: to hang
on to traditional thinking and conventional indirect and sub-
optimal techniques that can only detect osseous bone changes
when skeletal metastases have established themselves as bone
marrow metastases and at some unknown time point have
caused structural bone changes. Equally misleading is that
the reactive changes that they can detect may persist long after
the active cancer cells have disappeared, as a result of efficient
chemo- and/or radiotherapy.
Therefore, it is timely to state: Skeletal metastases are bone
marrow and not bone metastases! The true nature of skeletal
metastasis being bone marrow metastasis was highlighted
10 years ago by Basu et al. [17, 18], but apparently was
overlooked or ignored, although one should think that their
detailed account would suffice to convince even tenacious sup-
porters of the indirect imaging methods, especially if seeing it
from the patient’s viewpoint. Skeletal metastases develop as a
multistep process. When circulating tumor cells home to and
invade the highly vascularized bone marrow as metastatic
seeds, there follows a lag phase of unknown length comprising
a dormant phase and a more aggressive active phase, both of
which are not only regulated andmodified by a huge number of
factors in the microenvironment of the bone marrow stroma,
but are potentially mediated via sympathetic stimulation as well
[19–21]. In experimental tumor models, the dormant phase
may be relatively short, but in the clinical setting, such periods
of latency may last years, at least following excision of primary
tumors. Moreover, the tumors developing from metastatic dis-
seminations to the marrow exhibit a range of phenotypes which
may be characterized by the relative activity of tumor-
associated osteolysis and tumor-induced bone formation [19].
Thus, metastatic processes are present in the bone marrow long
before they give rise to the derangement of normal bone tissue
architecture, which is what is detectable by conventional x-ray,
Fig. 1 Main sites of metastases for some common cancer types, with lung
and breast routes to bones shown at shoulder level. Prostate cancer, the
third major source, is not shown because of the female model. Primary
cancers are denoted by B...cancer,^ and their main metastasis sites are
denoted by B...metastases.^ Source: Wikipedia. Bone metastases. The
images are in the public domain [3]
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CT, and SPECT and PET with bone-seeking radiopharmaceu-
ticals. Therefore, these modalities bear only indirect and not
real-time evidence of existing active tumor cells in the skeleton,
and the changes they depict may persist for long periods even if
the cancer cells have been eradicated.
Nonetheless, there are multiple comparisons in the literature
of conventional x-ray, CT, and SPECT in bone metastases, and
new ones continue to appear, now also with NaF-PET/CT and
NaF-PET/MR [22, 23] including a recent article which states
that there are no differences between planar bone scintigraphy,
SPECT and SPECT/CT, and NaF-PET/CT and NaF-PET/MR
in diagnosing bone metastases [24]. However, while such dif-
ference may be absent, the message is misleading, because the
comparisons included only indirect methods, which depict
bone changes and not the all-important bone marrow
metastases.
The consequence is that we must start using imaging tech-
niques that can detect, and preferably quantify, bone marrow
metastases as early as possible to guide management and in-
crease the possibility of cure, whereas indirect methods should
be abandoned. The only methodologies that can offer this
today are PET/CT and PET/MRI, applying FDG or some
Fig. 2 Upper panel: schematic
representation of the natural
shrinkage in red bone marrow
which resides throughout the
skeleton in the early years of life
and shrinks back to the axial
skeleton at the age of 20. This
explains why metastases in the
extremities are rarely seen in adult
patients, and underlines the
necessity of imaging the entire
skeleton when looking for
skeletal metastases in children,
whereas stopping at the mid-thigh
is defendable in adults. Lower
panel: whole-body FDG-PET
images of subjects (a) younger
than 20 years, and (b) 35, (c) 55,
and (d) 75 years of age. Note that
red marrow activity and
distribution in the spine, pelvic
bones, and femora are more
prominent at a younger age.
Reprinted with permission of
reference [27]
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more cancer-specific tracers such as prostate-specific mem-
brane antigen (PSMA)-associated probes. We suggest that de-
tection and quantification of bone marrow metastases should
in the future be based on PET/CT and possibly PET/MR im-
aging, applying tracers that target and depict the degree of
malignancy of active cancer cells proliferating in the red bone
marrow. For this purpose, FDG-PET is an excellent choice in
most cancers because it reflects tumor biology [25], meaning
that the rate of FDG uptake is an indication of the aggressive-
ness of tumor and metastasis and thus a valuable indicator of
prognosis. In fact, since cancers may differ in geno- and phe-
notype from the primary, to regional to distant metastasis in-
cluding bone marrow metastasis [26], and because bone mar-
row metastases comprise several phenotypes [19], the criti-
cized lack of specificity of FDG appears to be an advantage.
When looking for metastases to the skeleton, it is useful to
keep in mind that the red bone marrow in the first years of life
is present all the way to the distal end of our extremities, and
shrinks back to the axial skeleton during childhood (Fig. 2)
[27]. Some skeletal metastases from slow-growing tumors
such as thyroid, some types of breast, and prostate cancer
may be better assessed with more specific agents, the latter
with, for instance, PSMA-associated tracers. On the whole,
PET with tracers depicting cancer cells, their metabolism or
other useful characteristics, and not reactive changes in the
surrounding osseous tissue, are preferable—not only because
they depict active cancer, but also because these techniques
provide otherwise impossible quantification of the extent and
severity of cancerous skeletal involvement.
There are few comparisons with the most obvious molec-
ular imaging modality in cancer, FDG-PET/CT. They show
that FDG-PET/CT is superior in lung and breast cancer
[28–30]. There is no evidence that the combination of FDG
and NaF is warranted except in rare cases, because NaF-PET/
CT does not detect more osseous lesions than FDG-PET/CT
[31]. Moreover, NaF PET/CT has other challenges to deal
with. It has high specificity for osteoblastic lesions, but a gen-
erally low specificity is a larger problem with NaF than FDG,
as many benign lesions light up for a very long period of time
on NaF-PET/CT and because degenerative changes, the most
frequent abnormalities depicted by this modality, may have
intense and long-lasting NaF uptake, while FDG often shows
only weak accumulation. Healed fractures are often FDG-neg-
ative, but can remain NaF-positive for a long time [31]. The
literature lacks prospective longitudinal studies with FDG-
PET which show the temporal development of bone marrow
to bone metastases, and that the changes seen with CT and
SPECT during and after chemotherapy treatment do not nec-
essarily represent cancer any longer. In an elegant small retro-
spective study, it was recently demonstrated rather convinc-
ingly that marrow metastases are the early form of skeletal
metastases in breast cancer, and that early systemic treatment
may preclude the development of bone metastases [32].
In conclusion, we strongly advise that the concept of bone
marrow, instead of bone metastases, replace current miscon-
ceptions and current indirect imaging technologies, and bring
about much needed changes in the day-to-day practice and
guidelines regarding how to detect, gauge, and treat skeletal
metastases. Those who still believe in x-rays and bone scin-
tigraphy for this purpose may claim that access to PET is
limited and that the procedure is too costly. This has little
bearing, as FDG-PET has been shown to be cost-effective in
various cancers [33] and will prove to be so in bone marrow
metastases as well. We are dealing with a fatal disease of
growing incidence which requires accurate and individualized
assessment to guide treatment and improve the prospects of
affected patients. Nomethod other than PET, used correctly, is
as well suited to provide this.
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